Hyland Healthcare provides innovative, connected healthcare solutions designed to unlock the power of unstructured content and medical imaging across your enterprise. By seamlessly integrating this data with core systems like electronic health records (EHR) , Hyland delivers a comprehensive suite of content services and enterprise imaging tools tailored for modern healthcare organizations. Our solutions bring together documents, medical images, and clinically rich data to the people who need it most—accelerating business processes, streamlining clinical workflows, and enabling smarter, more informed decision-making. Key Features: • Enterprise Imaging Solutions: Support patient care with secure, consolidated medical imaging workflows that streamline operations and enhance clinical decisions. • Content & Image Integration: Embed documents and imaging data directly into your EHR workflows for a single source of truth. • Advanced Interoperability: Break down silos to create a continuous, holistic view of patient information across the healthcare enterprise. • Cloud Modernization: Enhance scalability and configurability with solutions that grow alongside your organization. Trusted by more than 50% of U.S. health systems and 85% of HIMSS EMRAM Stage 7 achievers, Hyland Healthcare empowers healthcare providers to deliver their best. Our customizable solutions simplify complexity, enabling your teams to focus on what truly matters—better patient outcomes and operational excellence. Discover how Hyland can transform your healthcare enterprise. Connect with an expert today.
Huna
Supercharging routine blood exams with AI, Huna turns massive data into accessible cancer care. By partnering with global leaders and leveraging one of the world’s largest oncology datasets, we deliver scalable solutions for early detection and risk stratification. Our platform supports the full cancer journey—from triage to diagnosis and beyond—transforming standard lab data into powerful clinical insights. Huna makes cutting-edge innovation usable by real-world healthcare systems tackling one of the world’s biggest health challenges.
Huckleberry Medical, LLC
Our mission is quite simple: provide top quality purchases and sales in the Used Medical Equipment market at fair pricing. We are not the least expensive company in the Used Diagnostic Imaging market, but we strive to give you the best value for your money. We also believe that the measure of a company is not in how they behave when the deals are good, but how they react when problems arise. We are masters at crisis management and getting deals back on track in the rare instances when that is needed. The Founder & CEO of Huckleberry Medical, LLC is Erik Baum. With over 30 years of experience in the industry, Erik has a reputation for caring about his customers’ needs, and handling complex MRI, CT Scanner, X-Ray, etc. equipment removals with expertise, including getting systems shipped around the world where they arrive intact. His core customers are extremely loyal because they know Erik gets the job done while protecting their interests.
Hong Kong Science and Technology Parks Corporation (HKSTP)
Hong Kong Science & Technology Parks Corporation (HKSTP) is the largest innovation and technology hub in Hong Kong. It fosters a vibrant ecosystem for startups, enterprises, and researchers, offering incubation, acceleration, and investment opportunities. HKSTP operates Science Park, InnoCentre, and InnoParks across Hong Kong, driving advancements in life sciences, AI, fintech, and more. With strong global partnerships, state-of-the-art facilities, and talent development programs, HKSTP accelerates innovation and commercialization, contributing to Hong Kong’s position as a regional I&T leader.
Hong Kong Pavilion
Hong Kong possesses a distinct advantage in biotechnology development, recognized as one of the world’s leading fundraising hubs for biotech companies. With robust research and development capabilities, HK is home to five universities ranked among the top 100 globally, while InnoHK serves as a pivotal hub for R&D in life and health technologies. 16 companies from Hong Kong Science and Technoloy Parks Corporation (HKSTP) participate BIO25 in HK Pavilion. | Hong Kong Science & Technology Parks Corporation (HKSTP) is a leading innovation and technology hub established in 2002. It fosters a vibrant ecosystem for startups, enterprises, and researchers, offering incubation, acceleration, and investment opportunities. HKSTP operates Science Park, InnoCentre, and InnoParks across Hong Kong, driving advancements in life sciences, AI, fintech, and more. With strong global partnerships, state-of-the-art facilities, and talent development programs, HKSTP accelerates innovation and commercialization, contributing to Hong Kong’s position as a regional I&T leader.
Hong Kong Baptist University: Institute for Innovation, Translation and Policy Research
Hong Kong Baptist College was founded by the Baptist Convention of Hong Kong in 1956. In 1983, it became a fully funded public tertiary institution, and the College gained university status just over a decade later. It was renamed Hong Kong Baptist University (HKBU) in 1994. The Institute for Innovation, Translation and Policy Research (ITPR) within HKBU serves to drive innovations, research and development, technology translation, and applications to enable HKBU to respond to emerging challenges and opportunities globally, nationally, as well as those under the aegis of the Hong Kong SAR Government’s top policy priority on innovation and technology development. ITPR strives to bridge the gap in technology readiness between academic innovation and industry applications. ITPR also helps to advance HKBU’s innovation capacity and enhance up- to mid-stream research and technology development capabilities through establishing collaborative platforms, engaging stakeholders, facilitating high-impact innovation and multidisciplinary R&D.
Holy Stone Healthcare Co., Ltd.
Holy Stone Healthcare Co., Ltd. (4194.TW) was established in Taipei in January 2001. Since 2009, the company has focused on a biopolymer drug delivery platform. Our R&D team has successfully developed “Hyaluronan Drug Delivery (HDD)” technology, which is a composition of hyaluronic acid in combination with a drug. This technology has been applied in the development of our new drug and medical device portfolio. | Holy Stone Healthcare Co., Ltd. (Listed in Taiwan Stock Exchange as HSHC, 4194.TW), pioneers in Hyaluronan based delivery systems, is a subsidiary of Holy Stone Enterprise Co., Ltd. (3026.TW). Our proprietary platform enables CD44-mediated site-selective uptake of hyaluronan-drug conjugates to where the drug is needed in a localized tissue. We offer tailored HA polymers to carry poorly water soluble and/or systemic-labile payloads that require localized tissue exposure. Our platform assets covering neurodegeneration, oncology, autoimmune diseases, retinal diseases, and RNA delivery are with proven efficacy in human and animals as illustrated below: •HylNeuro™ (ND108E) – CNS-targeted delivery across BBB for neurodegeneration •HylTargis™ (CA102N)– CD44-targeted delivery for solid tumors •HylMusa™ (IBD98-M)– Mucosal healing and anti-inflammation in GI tract •HylRetinX™ (AMD112)– Oral delivery across BRB for retinal diseases •HylCaryo™ –HA nanoparticle system for RNA/nucleic acid delivery and releasing ☆ Partnering Goals We are actively seeking out-licensing opportunities and/or strategic partnerships to co-develop our CNS, oncology, and ophthalmology assets. We are also offering payload conjugation services for your specific payloads for targeted delivery including RNA therapeutics. The detailed status of the assets is described below: 1. ND108E (HylNeuro™ ): Alzheimer’s Disease Therapy A CNS-targeted HA conjugate designed to restore cognition in post-menopausal Alzheimer’s patients. • Preclinical Data: Reversal of learning and memory deficits in behavioral models • Mechanism: Amyloid plaque reduction confirmed by PET imaging; increased spine density and restored ChAT activity • Status: IND-enabling studies in progress 2. CA102N (HylTargis™): Solid Tumor Therapy A dual-pathway (PI3K/mTOR + MAPK) HA conjugate targeting high-CD44 tumors, including KRAS G12D-mutant PDAC, TNBC, and mCRC. • Clinical Data: Phase I in mCRC showed prolonged PFS, improved DCR, and strong tolerability • Differentiation: >300 hrs tumor retention, 10x dose reduction with maintained efficacy • Next Steps: ODD application for PDAC; expansion to other tumor types 3. IBD98M (HylMusa™): Ulcerative Colitis Therapy An oral, multi-layer coated pellet combines HA and mesalamine for targeted colonic delivery. • Mode of Action: Forms a resorbable HA barrier over inflamed mucosa while delivering mesalamine locally • Clinical Status: Phase IIa showed significant symptom relief with a reduced drug burden; Phase IIb/III in preparation 4. AMD112 (HylRetinX™): Oral Wet AMD Therapy An oral HA conjugate with anti-angiogenic effects, designed to eliminate the need for intravitreal injections. • Efficacy: Demonstrated significant lesion size reduction in a laser-induced CNV model • Next Steps: Optimization of oral formulation and MOA confirmation underway ＃ Let’s Talk Please connect with us via appointments in the business forum 1 on 1 meeting, or visit our booth #2887 for more information on our data packages.
HiMedia Laboratories Pvt. Ltd.
HiMedia: Empowering Scientific Discovery in Cell Biology We extend our deepest gratitude to all our valued customers, distributors, and supporters. Your trust, collaboration, and continued partnership have been instrumental in our journey. With your unwavering support, we have reached new milestones, expanded our product portfolio, and made meaningful contributions to the advancement of cell biology research. We take immense pride in being a part of your scientific endeavors. The relationships we have cultivated over the years are at the heart of everything we do. Your feedback, loyalty, and commitment have continually inspired us to innovate, enhance our solutions, and deliver an ever-improving customer experience. As we look to the future, we are excited about the opportunities and challenges the coming year holds. With your continued support, we are confident in reaching new heights together. We remain dedicated to delivering greater value, enhanced product solutions, and exceptional technical support. Our focus is firmly on strengthening our collaborations and serving your evolving research needs. Our Commitment We are pleased to present our comprehensive price list, curated to serve not just as a product catalog, but also as a reflection of our dedication to the scientific community. Whether you’re a university lab, biotech startup, pharmaceutical company, or clinical research center, our mission is to provide the highest-quality tools and services to support your work in cell biology. Who We Are HiMedia is a science-led, innovation-driven organization specializing in products and solutions for cell biology research. With a strong foundation in media development, analytical sciences, and bioprocess engineering, we offer: Cell Culture Media & Reagents (Powder & Liquid) Cell Culture Platforms & Systems Primary & Stem Cells Assay Kits for Cell Proliferation, Cytotoxicity & Viability Advanced Analytical Services Cell-Based Services & Custom Research Solutions Bioprocess Development Platforms 3D Cell Culture Solutions Cleanroom Garments & Accessories With certifications under ISO 9001:2015 and ISO 13485:2016, our products undergo stringent quality control processes to ensure reproducibility, efficiency, and scientific accuracy. We invite you to explore our offerings and join us on this journey of scientific advancement and excellence.